AI Bias Analysis
4 models · Takes ~15 seconds
(MedPage Today) -- Real-world data suggested the dual GLP-1/GIP receptor agonist tirzepatide (Mounjaro, Zepbound) was associated with greater weight loss, but also muscle loss, compared with semaglutide (Ozempic, Wegovy), according to a medical...
Source
MedPage Today
Opens original article in a new tab
A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in a late-stage trial.
At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared the state of cancer research steady.
(MedPage Today) -- The FDA approved islatravir-doravirine (Idvynso) as a standalone, single-tablet regimen for treating HIV in virologically suppressed adults, Merck announced on Tuesday. Approval stipulates use of the oral combination in patients...
(MedPage Today) -- As medical organizations, lawmakers, advocates -- and even the lead actor from "The Pitt" -- laud the reauthorization of the Lorna Breen Act through fiscal year 2030, they're also urging millions of dollars to boost funding...
